Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · IEX Real-Time Price · USD
22.38
-0.78 (-3.37%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Akero Therapeutics Employees
Akero Therapeutics had 56 employees as of December 31, 2023. The number of employees increased by 18 or 47.37% compared to the previous year.
Employees
56
Change (1Y)
18
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$3,201,286
Market Cap
1.55B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 56 | 18 | 47.37% |
| Dec 31, 2022 | 38 | 4 | 11.76% |
| Dec 31, 2021 | 34 | 12 | 54.55% |
| Dec 31, 2020 | 22 | 8 | 57.14% |
| Dec 31, 2019 | 14 | 4 | 40.00% |
| Dec 31, 2018 | 10 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| National HealthCare | 13,123 |
| Teladoc Health | 5,600 |
| Galapagos NV | 1,123 |
| Veracyte | 815 |
| InMode | 581 |
| Mirum Pharmaceuticals | 264 |
| Kura Oncology | 142 |
| Keros Therapeutics | 136 |
AKRO News
- 4 days ago - Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm - GlobeNewsWire
- 7 days ago - AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
- 7 days ago - FINAL AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - Accesswire
- 7 days ago - AKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit - PRNewsWire
- 8 days ago - The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO) - Business Wire
- 8 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO - PRNewsWire
- 8 days ago - AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO - GlobeNewsWire
- 8 days ago - INVESTOR DEADLINE TOMORROW: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKRO - Accesswire